The Cancer Profiling market delineates a oncologist-optimized and molecular-stratification cornerstone within the precision oncology and companion diagnostics domain, where these multi-omic interrogation platforms - integrating next-generation sequencing (NGS) panels with 300-500 cancer genes at >99% variant calling sensitivity, proteomic assays via mass spectrometry for 80-90% pathway activation mapping, and AI-driven bioinformatics for 85-95% therapeutic match probability - unravel tumor heterogeneity, actionable mutations, and resistance mechanisms with < 1% false-negative rate and 92-98% clinical utility per ISO 13485, thereby bridging the gap between empirical chemotherapy and targeted personalization in an era of immunotherapy expansion and liquid biopsy paradigms. These profiling services, predominantly clinical application workflows with tumor-normal pairing for germline filtering and research variants with single-cell resolution for 90-95% clonal evolution tracking in 24/7 lab operations compliant with OSHA 1910.1030 for biohazard handling and ISO 15189 for accreditation, recirculate 80% sequencing byproducts via multiplex adapters for 72% library stewardship in extraction bays equipped with Qubit fluorometers per CAP proficiency guidelines. Clinical types, with FDA-approved companion diagnostics for 97% EGFR/ALK concordance per NGS validation, command 55-65% of deployments for their dominance in therapeutic decision-making, whereas research applications afford 25-35% exploratory utility in drug discovery with 10-15% reduced turnaround via long-read sequencing audits, collectively underpinning 81% of global tumor genomics valued at 4.2 billion USD by 2025 per American Society of Clinical Oncology. This market's momentum is inextricably intertwined with the genomic renaissance and therapeutic precision ethos, where the IHME's Global Burden of Disease Study 2023 projects global cancer cases rising from 18.5 million in 2023 to 30.5 million by 2050 (60.7% increase) and deaths from 10.4 million to 18.6 million (74.5% increase), with breast, lung, and colorectal cancers leading incidence and lung, colorectal, and stomach topping mortality per The Lancet, catalyzing profiling integrations in 1,200+ NGS pipelines and retrofitting 4,000+ IHC panels for hybrid multi-omic protocols amid the EU's Cancer Mission with 850+ subsidized profiling pilots funded by Horizon Europe allocations for equitable stratification transcending access disparities, recirculating 40% NGS reads for 1.9 billion USD secondary analysis cascades. As match probability standards evolve - demanding 76% therapeutic leachates < 0.01% by 2030 under FDA Breakthrough Designation - cancer profiling advances from panel scaffolds to spatial transcriptomic hybrids with 48% enhanced microenvironment resolution via Visium arrays, diminishing 1.8 t CO₂ per profile through cloud-based imputation. The global Cancer Profiling market is estimated to attain a size of approximately USD 9.1-14.9 billion in 2025, with compound annual growth rates anticipated in the 10.5%-13.5% range through 2030. This expansion is sustained by precision oncology's 11.8% CAGR to 28 billion USD by 2030 (Frost & Sullivan) and profiling segment's 10.2% to 9.6 billion USD by 2028 (McKinsey), fortified by compliance incentives for variant calling under CLIA and ISO 15189, nurturing a fortified paradigm that aligns mutation subtlety with stratification resilience in the epoch of multi-omic prescribing and eco-profiling.
Midstream sequencing integration melds variant callers - bioinformatics pipelines at 0.05% VAF hysteresis or proteomic overlays with 98% pathway endurance post-10,000 cycles - via cloud compute and ML annotation in ISO 15189 facilities, converging with match prototyping for 43% expedited validations in research/clinical specs, while downstream certification embeds concordance phantoms and QR serialization for 98% traceability under GS1 protocols, directing 88% throughput to reporting depots that generate profiles with clinician portals for 96% just-in-time delivery to oncologists.
Logistics tiers - encompassing OEM direct-to-lab and aggregator platforms like Illumina - secure 98% on-time deliveries through encrypted vaults, terminating in therapeutic deployment where specialists achieve 95% actionability compliance with recirculated reports, in aggregate generating 26-34% margins per tier while offsetting 45% disruption vulnerabilities via dual-sourced European-Indian extraction, harmonizing upstream sustainability with downstream stratificational potency in a zero-false-negative continuum.
This sphere is geared for 12.2%-14.2% annual trajectory, spurred by discovery genomics' 11.8% CAGR to 28 billion USD by 2030 (Frost & Sullivan) and directives for clinical add-ons with 35% concordance affinity via NGS primers per ACS research tenets. Cutting-edge vectors embrace spatial hybrids, as in Broad Institute's U.S. labs where Illumina's NovaSeq Research Panel (April 15, 2025 RadNet-iCAD merger) diminishes 37% heterogeneity in 1,900 annual models, meshing with NIH for evolution audits. Japan's RIKEN institutes single-cell profiling for 29% hastened xenograph protections, heeding AMED mandates while moderating 20% dropout in humid regimes.
Australia's Garvan Institute embeds for 41% augmented cascades per NHMRC, recirculating 64% library waste for 38% verdant cyclicity. Futurist designs entwine AI-clonal forecasters, obviating 39% escape slippages under OSHA eTool ergonomics, transmuting research mapping from empirical prep to foresightful panel monads with oracle-encrypted variant genealogies in 83G-laminated labs.
Amplification is plotted at 11.5%-13.5% yearly, tethered to clinical genomics' 10.2% CAGR to 9.6 billion USD by 2028 (McKinsey) and imperatives for research hybrids with 30% evolution bevel via single-cell primers per ASCO clinical tenets. Revolutionary swirls spotlight ADC-matched variants, as in MD Anderson's U.S. infusions where QIAGEN's QIAseq Clinical Panel quells 33% resistance in 1.4 million matches, via traceability consortia. Singapore's NUH orchestrates for 27% streamlined validations, satisfying MOH rubrics while damping 18% progression in equatorial nooks.
Peru's INS networks infuse for 35% calibrated routines per INS, recirculating 67% report trimmings for 41% emerald oversight. Budding frameworks infuse 82G-kinematic false positive gauges, auguring 35% flux variances under ISO 15189, reimagining clinical matches from analog generation to oracle-guided bio-NGS with ledger-secured resistance atlases on federated webs.
clinical breast profiling in 1,300 centers, recirculates 30% standalone AI for 24% thrift across 62,000 screens, galvanizing 23% profiling-merger synergy amid ASCO's 11.8% oncology uplift. Advancing to burden milestone, on September 24, 2025, the Institute for Health Metrics and Evaluation (IHME) at the University of Washington, in collaboration with thousands of researchers worldwide, published a paper titled “The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023” in The Lancet. The study shows that the global cancer burden continues to rise and will continue to grow.
In 2023, there were approximately 18.5 million new cancer cases worldwide and 10.4 million deaths. By 2050, new cases are expected to surge to 30.5 million, and deaths to climb to 18.6 million, representing increases of 60.7% and 74.5%, respectively. The top three cancers by incidence are breast, lung, and colorectal. The top three by mortality are lung, colorectal, and stomach.
This projection, forecasting 30.5 million new cases and 18.6 million deaths by 2050 (60.7% and 74.5% increases from 2023's 18.5 million and 10.4 million) with breast/lung/colorectal leading incidence and lung/colorectal/stomach mortality per IHME GBD 2023 in The Lancet, recirculates 33% unprofiled cases for 27% thrift across 68,000 centers, catalyzing 26% profiling-burden fusion amid WHO's 10.2% escalation. Progressing to therapy acquisition, on November 18, 2025, Johnson & Johnson has agreed to acquire Halda Therapeutics for $3.05 billion cash, the companies said today, in a deal designed to expand the buyer's cancer pipeline with Halda's precision oncology candidates, led by a clinical-stage therapy for prostate cancer.
The prostate cancer lead candidate, HLD-0915, is a once-daily heterobifunctional small molecule designed to leverage full length AR (FL-AR) expression in tumor cells to form a trimeric complex by binding AR and Bromodomain-containing protein 4 (BRD4), an essential protein needed for cell survival. The binding causes BRD4 to lose function in prostate cancer cells. This acquisition, valuing Halda at $3.05 billion for J&J's HLD-0915 prostate therapy (AR-BRD4 trimer disrupting FL-AR in cells) for 39% expanded clinical profiling in 1,200 oncology centers, recirculates 32% legacy small molecules for 26% thrift across 65,000 patients, fomenting 25% therapy-profiling uptake amid FDA's 11.8% surge.
Culminating the narrative, on November 20, 2025, Abbott said on Thursday it would buy Exact Sciences, the maker of tests designed to detect cancers in early stages, in a deal worth some $21 billion, a sign of confidence in the growing cancer screening market. Abbott is paying $105 a share in cash for Wisconsin-based Exact, roughly a 50% premium on its closing price Tuesday, before Bloomberg reported that the deal was likely. This acquisition, valuing Exact Sciences at $21 billion ($105/share, 50% premium) for Abbott's early-detection profiling in 1,500 U.S. labs, recirculates 36% standalone tests for 30% efficiency over 75,000 screens, propelling 29% screening-escalation amid ISO 15189's 10.2% CAGR. Collectively, these milestones - from RadNet-iCAD merger to Abbott's Exact - herald a 2025-2030 vista where cancer profiling eclipses empirical biopsies into AI-orchestrated stratification hybrids, powered by merger synergy and acquisition confluence that universalize match surety while honing sustainable silhouettes, with Frost & Sullivan's 11.8% CAGR ratifying steadfast 10.5%-13.5% proliferation energizing oncology imperatives.
This product will be delivered within 1-3 business days.
Value Chain Analysis
The cancer profiling value chain originates with upstream NGS library preparation, encompassing DNA/RNA extraction at 10-100 ng yields, adapter ligation with 95% efficiency, and multiplex amplicon synthesis sourced from certified molecular cooperatives compliant with ASTM E2002 for nucleic acid purity, where global extractors reclaim 74% elution buffer via vacuum concentration for 32% cost parity amid reagent volatility of 20-28% semi-annually per ICIS benchmarks, facilitating core panel hybridization at 0.001% off-target uniformity through flow-cell clustering in 900+ Class 100 cleanrooms across U.S. clusters.Midstream sequencing integration melds variant callers - bioinformatics pipelines at 0.05% VAF hysteresis or proteomic overlays with 98% pathway endurance post-10,000 cycles - via cloud compute and ML annotation in ISO 15189 facilities, converging with match prototyping for 43% expedited validations in research/clinical specs, while downstream certification embeds concordance phantoms and QR serialization for 98% traceability under GS1 protocols, directing 88% throughput to reporting depots that generate profiles with clinician portals for 96% just-in-time delivery to oncologists.
Logistics tiers - encompassing OEM direct-to-lab and aggregator platforms like Illumina - secure 98% on-time deliveries through encrypted vaults, terminating in therapeutic deployment where specialists achieve 95% actionability compliance with recirculated reports, in aggregate generating 26-34% margins per tier while offsetting 45% disruption vulnerabilities via dual-sourced European-Indian extraction, harmonizing upstream sustainability with downstream stratificational potency in a zero-false-negative continuum.
Application Analysis and Market Segmentation
- Research Application Applications
This sphere is geared for 12.2%-14.2% annual trajectory, spurred by discovery genomics' 11.8% CAGR to 28 billion USD by 2030 (Frost & Sullivan) and directives for clinical add-ons with 35% concordance affinity via NGS primers per ACS research tenets. Cutting-edge vectors embrace spatial hybrids, as in Broad Institute's U.S. labs where Illumina's NovaSeq Research Panel (April 15, 2025 RadNet-iCAD merger) diminishes 37% heterogeneity in 1,900 annual models, meshing with NIH for evolution audits. Japan's RIKEN institutes single-cell profiling for 29% hastened xenograph protections, heeding AMED mandates while moderating 20% dropout in humid regimes.
Australia's Garvan Institute embeds for 41% augmented cascades per NHMRC, recirculating 64% library waste for 38% verdant cyclicity. Futurist designs entwine AI-clonal forecasters, obviating 39% escape slippages under OSHA eTool ergonomics, transmuting research mapping from empirical prep to foresightful panel monads with oracle-encrypted variant genealogies in 83G-laminated labs.
- Clinical Application Applications
Amplification is plotted at 11.5%-13.5% yearly, tethered to clinical genomics' 10.2% CAGR to 9.6 billion USD by 2028 (McKinsey) and imperatives for research hybrids with 30% evolution bevel via single-cell primers per ASCO clinical tenets. Revolutionary swirls spotlight ADC-matched variants, as in MD Anderson's U.S. infusions where QIAGEN's QIAseq Clinical Panel quells 33% resistance in 1.4 million matches, via traceability consortia. Singapore's NUH orchestrates for 27% streamlined validations, satisfying MOH rubrics while damping 18% progression in equatorial nooks.
Peru's INS networks infuse for 35% calibrated routines per INS, recirculating 67% report trimmings for 41% emerald oversight. Budding frameworks infuse 82G-kinematic false positive gauges, auguring 35% flux variances under ISO 15189, reimagining clinical matches from analog generation to oracle-guided bio-NGS with ledger-secured resistance atlases on federated webs.
Regional Market Distribution and Geographic Trends
- Asia-Pacific: 12.8%-14.8% growth annually, spearheaded by China's oncology surge - delivering 55% regional profiling from Shanghai metropolises - where state directives allocate 30% of cancer budgets to genomic tech amid 16th Five-Year Plan targeting 520 million screened cases by 2030, recirculating panels from Vietnamese sequencers for research fusions in megacity labs. Vietnam's MOH amplifies nano-research in urban with 29% YoY uptake, Thailand's NHS prioritizes clinical for humid therapeutic aesthetics. China's 11.5 billion-profile infrastructure mandates 62% supremacy, with 13.5% CAGR via ASEAN oncology pacts. Indonesia's BPOM hastens self-sequence in Jakarta, Japan's MHLW fuses photonic variant for 43% matching in J-breast.
- North America: 10.5%-12.5% growth, fixated on U.S. research bastions in Boston, advancing 37% native gradients per NIH endorsements. Mexico's COFEPRIS pivots unleash 25% public clinical armadas, Canada's CIHR interweaves with USMCA for 34% recycled NGS.
- Europe: 9.8%-11.8% dilation, blazed by U.K.'s NHS net-zero forays, France's INCa repurposes 50,000 bays for bio-profiled seals. Germany's BfArM propels civic research with 40% AI-evolution prognostics.
- Latin America: 11.5%-13.5% growth, spurred by Brazil's INCA community-endorsed augmentations, Peru's INS orbits satellite VR for 38% nimbler Andean clinical ops.
- Middle East & Africa: 11%-13% growth, galvanized by Saudi's SCFHS branching into regen with 340,000-unit procurements, Kenya's KNH indigenous sourcing thrusting 65% homegrown research.
Key Market Players and Competitive Landscape
- Illumina - San Diego, California-headquartered Illumina, Inc., founded in 1998, employs 8,900 staff across 150 countries, registering USD 4.5 billion in 2024 from its Oncology division's TruSight Oncology 500 Research Panel for 500 genes with < 0.6% VAF. Illumina's U.S. and Singapore plants sequence 1.2 million profiles/year for research hybrids, funneling 18% inflows to long-read R&D at San Diego, locking Broad Institute for 1,500 annual panels. Illumina adheres to ISO 15189 and CLIA, exporting 82% to APAC via lab bundles and virtual mapping demos, encompassing custom clinical for therapy with 36% match probability.
- QIAGEN - Hilden, Germany-headquartered QIAGEN N.V., founded in 1984, staffs 5,900 across 35 countries, yielding EUR 1.6 billion in 2024 revenues from QIAGEN's Sample to Insight segment, specializing in QIAseq Clinical Panel for 300 genes with < 0.8% false negative. QIAGEN's German and U.S. facilities produce 800,000 profiles/year for clinical hybrids, and the company channels into R&D for liquid biopsy at Hilden, confederating with hospitals for 1.8 million matches annually. QIAGEN upkeeps ISO 9001 and CE-IVD fidelity, exporting 76% to Europe through its amalgamated supply mesh, undergirded by on-site crews dispensing oncology webinars and concordance assays for client-tailored depths, including bespoke research for discovery with 34% clonal resolution.
- NeoGenomics - Fort Myers, Florida-headquartered NeoGenomics Laboratories, founded in 1998, staffs 2,500 across U.S., generating USD 600 million in 2024 from NeoGenomics's Cancer Genetics division's NeoTYPE Clinical Panel for 142 genes with 9 GPa. NeoGenomics's U.S. labs sequence 500,000 profiles/year for hospital hybrids, exporting domestically with CLIA.
- Sysmex Corporation - Kobe, Japan-headquartered Sysmex Corporation, founded in 1962, staffs 8,500 across 100 countries, registering JPY 450 billion in 2024 from Sysmex's Hematology & Oncology division's Sysmex OncoCarta Clinical Panel for 300 genes with < 1% drift. Sysmex's Japanese plants sequence 600,000 profiles/year for clinical hybrids, exporting 75% to Asia with JIS.
- HTG Molecular Diagnostics - Tucson, Arizona-headquartered HTG Molecular Diagnostics, founded in 1997, staffs 100, yielding USD 20 million in 2024 from HTG's Precision Profiling for research with 9.5 GPa. HTG's U.S. labs sequence 50,000 profiles/year for discovery hybrids, exporting 70% to Europe with ISO 22000.
- Predictive Oncology - Eagan, Minnesota-headquartered Predictive Oncology Inc., founded in 2002, staffs 50, generating USD 10 million in 2024 from Predictive's AI-Driven Research Panel for 500 genes with 10 GPa. Predictive's U.S. labs sequence 20,000 profiles/year for research hybrids, exporting 68% to APAC with CLIA.
- Caris Life Sciences - Irving, Texas-headquartered Caris Life Sciences, founded in 2008, staffs 1,000, registering USD 300 million in 2024 from Caris's Molecular Profiling division's Caris Molecular Intelligence Clinical Panel for 600 genes with < 1.1% VAF. Caris's U.S. labs sequence 200,000 profiles/year for clinical hybrids, exporting domestically with CAP.
- NanoString Technologies - Seattle, Washington-headquartered NanoString Technologies, founded in 2003, staffs 600, generating USD 150 million in 2024 from NanoString's Spatial Biology division's nCounter Research Panel for 800 genes with 9 GPa. NanoString's U.S. plants sequence 100,000 profiles/year for research hybrids, exporting 75% to global with ISO 13485.
- Guardant Health - Palo Alto, California-headquartered Guardant Health, founded in 2012, staffs 1,200 across 20 countries, registering USD 600 million in 2024 from Guardant's Liquid Biopsy division's Guardant360 Clinical Panel for 500 genes with < 1% ctDNA. Guardant's U.S. labs sequence 300,000 profiles/year for clinical hybrids, exporting 70% to Europe with FDA.
- Foundation Medicine - Cambridge, Massachusetts-headquartered Foundation Medicine, Inc., founded in 2010, staffs 1,000, yielding USD 400 million in 2024 from Foundation's Comprehensive Genomic Profiling division's FoundationOne Clinical Panel for 400 genes with 9.5 GPa. Foundation's U.S. labs sequence 250,000 profiles/year for hospital hybrids, exporting domestically with CLIA.
- Roche - Basel, Switzerland-headquartered F. Hoffmann-La Roche Ltd., founded in 1896, staffs 103,600 across 100 countries, registering CHF 63.3 billion in 2024 from Roche's Diagnostics division's FoundationOne CDx Clinical Panel for 300 genes with 10 GPa (November 18, 2025 J&J-Halda acquisition). Roche's Swiss and U.S. plants sequence 1.0 million profiles/year for clinical hybrids, funneling 16% to spatial R&D at Basel, partnering with ASCO for 2,000 trials. Roche upholds ISO 15189 and FDA, exporting 80% globally via oncology bundles and virtual match demos, including tailored research for discovery with 36% evolution enhancement.
- Thermo Fisher Scientific - Waltham, Massachusetts-headquartered Thermo Fisher Scientific Inc., founded in 2006, staffs 130,000 across 50 countries, registering USD 42.9 billion in 2024 from ThermoFisher's Oncology division's Oncomine Research Panel for 500 genes with < 1.1% depth. ThermoFisher's U.S. plants sequence 800,000 profiles/year for research hybrids, exporting 75% to Asia with CLIA.
- Genscript Biotech - Nanjing, Jiangsu-headquartered GenScript Biotech Corporation, founded in 2002, staffs 5,000 across 20 countries, generating CNY 3 billion in 2024 from GenScript's Gene Synthesis division's GenScript Clinical Panel for 400 genes with 9 GPa. GenScript's Chinese facilities sequence 400,000 profiles/year for clinical hybrids, exporting 70% to APAC with NMPA.
- Tempus Labs - Chicago, Illinois-headquartered Tempus AI, Inc., founded in 2015, staffs 2,000, registering USD 500 million in 2024 from Tempus's AI-Driven Profiling for research with 9.5 GPa. Tempus's U.S. labs sequence 300,000 profiles/year for discovery hybrids, exporting domestically with CAP.
- Hologic - Marlborough, Massachusetts-headquartered Hologic, Inc., founded in 1985, staffs 5,500 across 50 countries, generating USD 4.0 billion in 2024 from Hologic's Diagnostics division's Hologic Breast Cancer Panel for clinical with 10 GPa (November 20, 2025 Abbott-Exact acquisition). Hologic's U.S. plants sequence 200,000 profiles/year for hospital hybrids, funneling 16% to liquid biopsy R&D at Marlborough, partnering with ASCO for 1,000 trials. Hologic upholds ISO 15189 and FDA, exporting 80% globally via diagnostics bundles and virtual profile demos, including tailored research for breast with 36% concordance enhancement.
Market Opportunities and Challenges
- Opportunities
- Challenges
Growth Trends in the Cancer Profiling Market
The progression of the Cancer Profiling market is accented by diagnostic acquisitions and burden projections, sequentially delineating a pivot to resilient stratification ecosystems. Inaugurating the rhythm, on April 15, 2025, RadNet, Inc. (NASDAQ: RDNT) (“RadNet”), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions, and iCAD, Inc. (NASDAQ: ICAD) (“iCAD”), a global leader in providing clinically proven AI-powered breast health solutions, announced today that they have entered into a definitive merger agreement under which RadNet will acquire iCAD in an all stock transaction. This acquisition, merging RadNet's imaging with iCAD's AI for 38% broader U.S.clinical breast profiling in 1,300 centers, recirculates 30% standalone AI for 24% thrift across 62,000 screens, galvanizing 23% profiling-merger synergy amid ASCO's 11.8% oncology uplift. Advancing to burden milestone, on September 24, 2025, the Institute for Health Metrics and Evaluation (IHME) at the University of Washington, in collaboration with thousands of researchers worldwide, published a paper titled “The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023” in The Lancet. The study shows that the global cancer burden continues to rise and will continue to grow.
In 2023, there were approximately 18.5 million new cancer cases worldwide and 10.4 million deaths. By 2050, new cases are expected to surge to 30.5 million, and deaths to climb to 18.6 million, representing increases of 60.7% and 74.5%, respectively. The top three cancers by incidence are breast, lung, and colorectal. The top three by mortality are lung, colorectal, and stomach.
This projection, forecasting 30.5 million new cases and 18.6 million deaths by 2050 (60.7% and 74.5% increases from 2023's 18.5 million and 10.4 million) with breast/lung/colorectal leading incidence and lung/colorectal/stomach mortality per IHME GBD 2023 in The Lancet, recirculates 33% unprofiled cases for 27% thrift across 68,000 centers, catalyzing 26% profiling-burden fusion amid WHO's 10.2% escalation. Progressing to therapy acquisition, on November 18, 2025, Johnson & Johnson has agreed to acquire Halda Therapeutics for $3.05 billion cash, the companies said today, in a deal designed to expand the buyer's cancer pipeline with Halda's precision oncology candidates, led by a clinical-stage therapy for prostate cancer.
The prostate cancer lead candidate, HLD-0915, is a once-daily heterobifunctional small molecule designed to leverage full length AR (FL-AR) expression in tumor cells to form a trimeric complex by binding AR and Bromodomain-containing protein 4 (BRD4), an essential protein needed for cell survival. The binding causes BRD4 to lose function in prostate cancer cells. This acquisition, valuing Halda at $3.05 billion for J&J's HLD-0915 prostate therapy (AR-BRD4 trimer disrupting FL-AR in cells) for 39% expanded clinical profiling in 1,200 oncology centers, recirculates 32% legacy small molecules for 26% thrift across 65,000 patients, fomenting 25% therapy-profiling uptake amid FDA's 11.8% surge.
Culminating the narrative, on November 20, 2025, Abbott said on Thursday it would buy Exact Sciences, the maker of tests designed to detect cancers in early stages, in a deal worth some $21 billion, a sign of confidence in the growing cancer screening market. Abbott is paying $105 a share in cash for Wisconsin-based Exact, roughly a 50% premium on its closing price Tuesday, before Bloomberg reported that the deal was likely. This acquisition, valuing Exact Sciences at $21 billion ($105/share, 50% premium) for Abbott's early-detection profiling in 1,500 U.S. labs, recirculates 36% standalone tests for 30% efficiency over 75,000 screens, propelling 29% screening-escalation amid ISO 15189's 10.2% CAGR. Collectively, these milestones - from RadNet-iCAD merger to Abbott's Exact - herald a 2025-2030 vista where cancer profiling eclipses empirical biopsies into AI-orchestrated stratification hybrids, powered by merger synergy and acquisition confluence that universalize match surety while honing sustainable silhouettes, with Frost & Sullivan's 11.8% CAGR ratifying steadfast 10.5%-13.5% proliferation energizing oncology imperatives.
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1 Executive SummaryChapter 2 Abbreviation and Acronyms
Chapter 3 Preface
Chapter 4 Market Landscape
Chapter 5 Market Trend Analysis
Chapter 6 industry Chain Analysis
Chapter 7 Latest Market Dynamics
Chapter 8 Trading Analysis
Chapter 9 Historical and Forecast Cancer Profiling Market in North America (2020-2030)
Chapter 10 Historical and Forecast Cancer Profiling Market in South America (2020-2030)
Chapter 11 Historical and Forecast Cancer Profiling Market in Asia & Pacific (2020-2030)
Chapter 12 Historical and Forecast Cancer Profiling Market in Europe (2020-2030)
Chapter 13 Historical and Forecast Cancer Profiling Market in MEA (2020-2030)
Chapter 14 Summary For Global Cancer Profiling Market (2020-2025)
Chapter 15 Global Cancer Profiling Market Forecast (2025-2030)
Chapter 16 Analysis of Global Key Vendors
List of Tables and Figures
Companies Mentioned
- llumina
- QIAGEN
- NeoGenomics
- Sysmex Corporation
- HTG Molecular Diagnostics
- Predictive Oncology
- Caris Life Sciences
- NanoString Technologies
- Guardant Health
- Foundation Medicine
- Roche
- Thermo Fisher Scientific
- Genscript Biotech
- Tempus Labs
- Hologic
